Influence of nitric oxide on morphine-induced amnesia and interactions with dopaminergic receptor agents

Physiology & Behavior
Ameneh RezayofMohammad-Reza Zarrindast

Abstract

The interactions of dopaminergic receptors and nitric oxide (NO) with morphine-induced memory of passive avoidance have been investigated in mice. Pre-training administration of morphine (1, 3 and 5 mg/kg, s.c.) dose-dependently decreased the learning of a one-trial passive avoidance task. Pre-training administration of L-arginine, a nitric oxide precursor (50, 100 and 200 mg/kg, i.p.), alone did not affect memory formation. The drug (100 and 200 mg/kg) decreased significantly amnesia induced by pre-training morphine (5 mg/kg). Pre-training administration of L-NAME (N(G)-nitro-L-arginine methyl ester), a nitric oxide synthase (NOS) inhibitor (20 and 30 mg/kg, i.p.), dose-dependently impaired memory formation. In addition, co-pretreatment of different doses of L-NAME (10, 20 and 30 mg/kg) with lower dose of morphine (1 mg/kg), which did not induce amnesia by itself, caused inhibition of memory formation. Pre-training administration of apomorphine, a dopaminergic receptor agonist (0.25, 0.5 and 1 mg/kg, i.p.), alone also did not affect memory formation, but morphine-induced amnesia was significantly inhibited by pretreatment with apomorphine (0.5 and 1 mg/kg, 5 min, i.p.). On the other hand, the inhibition of morphine-induced amn...Continue Reading

References

Nov 9, 1978·Life Sciences·M Gallagher, B S Kapp
Oct 20, 1992·European Journal of Pharmacology·Y A KolesnikovG W Pasternak
Jan 1, 1991·Psychopharmacology·J W Spain, G C Newsom
Jan 1, 1990·Psychopharmacology·M NishimuraH Kaneto
Jul 1, 1990·Pharmacology, Biochemistry, and Behavior·T CanliK A Miczek
Feb 1, 1985·Physiology & Behavior·F K Jellestad, H K Bakke
Nov 21, 1994·Neuroreport·A StrasserM Spatz
May 1, 1996·Neurobiology of Learning and Memory·C M Baratti, S R Kopf
Apr 1, 1996·Pharmacology, Biochemistry, and Behavior·T KivastikA Zharkovsky
Nov 12, 1996·Proceedings of the National Academy of Sciences of the United States of America·D Yanagihara, I Kondo
Jan 1, 1996·Advances in Neuroimmunology·Y Liu
Mar 27, 1997·Nature·R I WilsonH L Haas
Jul 1, 1997·Molecular Psychiatry·H Schulman
Jan 24, 1998·European Journal of Pharmacology·S SigalaP Spano
Mar 28, 1998·Neuropharmacology·G Telegdy, R Kokavszky
May 14, 1998·Neuroscience and Biobehavioral Reviews·R J Beninger, R Miller
Jun 5, 1999·Behavioral Neuroscience·L A Bruins Slot, F C Colpaert
Sep 4, 1999·Behavioural Brain Research·I IzquierdoD M Barros
Jun 3, 2000·Annual Review of Pharmacology and Toxicology·P Y LawH H Loh
Mar 16, 2001·Progress in Neurobiology·H Prast, A Philippu
Aug 9, 2002·European Journal of Pharmacology·Azam GholamiMohammad-Reza Zarrindast
Oct 24, 2002·European Journal of Pharmacology·Mohammad Reza ZarrindastHedayat Sahraei
Jul 26, 2003·Progress in Neurobiology·Thérèse M Jay
Apr 21, 2004·Behavioural Pharmacology·M R ZarrindastB Djahanguiri
Aug 13, 2004·European Journal of Pharmacology·Mohammad-Reza Zarrindast, Ameneh Rezayof
Aug 24, 2004·The International Journal of Neuropsychopharmacology·Massimo GuarnaEnrica Bianchi
Aug 28, 2004·Trends in Neurosciences·Evangelos G Antzoulatos, John H Byrne
Dec 2, 2004·Peptides·Richard J Bodnar, Gad E Klein
Dec 8, 2004·Behavioural Brain Research·Daphna ShohamyMark A Gluck
Jul 27, 2005·Behavioural Brain Research·Thomas StecklerJos Prickaerts

❮ Previous
Next ❯

Citations

Mar 2, 2011·Psychopharmacology·Raquele Kipper MarianiMaribel Antonello Rubin
Nov 19, 2009·Journal of Anesthesia·Noboru TodaHiroshi Toda
Sep 3, 2014·Pharmacology, Biochemistry, and Behavior·Mohammad NasehiMohammad-Reza Zarrindast
Oct 30, 2012·Physiology & Behavior·Mohammad NasehiMohammad Reza Zarrindast
Mar 2, 2010·European Journal of Pharmacology·Mohammad NasehiMohammad Reza Zarrindast
May 20, 2009·Neurobiology of Learning and Memory·Mohammad NasehiMohammad Reza Zarrindast
May 16, 2008·Physiology & Behavior·Niloufar DarbandiMohammad-Reza Zarrindast
Dec 11, 2007·Neurobiology of Learning and Memory·Ameneh RezayofYassaman Rassouli
Oct 24, 2007·Peptides·Richard J Bodnar
Oct 19, 2006·Life Sciences·Ameneh RezayofMohammad-Reza Zarrindast
Mar 5, 2008·European Journal of Pharmacology·Lotfollah KhajehpourMohammad-Reza Zarrindast
Dec 3, 2014·European Journal of Pharmacology·Siamak BeheshtiMehdi Eivani
Oct 4, 2011·Journal of Psychopharmacology·Mohammad NasehiMohammad Reza Zarrindast
Jun 7, 2007·Behavioural Pharmacology·Mohammad-Reza ZarrindastShamseddin Ahmadi
Jul 21, 2007·Acta Pharmacologica Sinica·Chang LiuMin Hong

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.